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Volume 57, Number 5S Abstracts 55SPS76. PS78.Elderly Patients Started on Hemodialysis (HD) With
a Tunneled Dialysis Catheter (TDC) Have Similar
Long Term Survival After Arteriovenous Fistula
(AVF) or Arteriovenous Graft (AVG) Placement
Theodore H. Yuo, Rabih Chaer, Ellen D. Dillavou, Luke
K. Marone, Michel S. Makaroun. Surgery, University of
PIttsburgh, Pittsburgh, Pa
Objectives: SVS guidelines suggest AVF is associated
with a survival advantage over AVG. However, AVF often
require months to become functional, increasing TDC use
in patients starting HD with TDC. We sought to compare
survival in ESRD patients based on HD access type.
Methods: Using US Renal Data System (USRDS)
databases, we identiﬁed incident HD patients in 2005 and
followed them through 2008. Initial access type was assessed
using USRDS data collection forms. Attempts at AVF and
AVG creation were identiﬁed by CPT codes. Patients were
divided into groups based on whether an attempt at AVF
or AVG was undertaken within 3 months after initiation of
HD. Log-rank tests were used for pairwise survival compar-
isons, stratiﬁed by age. The primary outcome was vital status.
Results: We analyzed 46,672 patients who started HD
in 2005 and survived at least 3 months. TDC was the initial
access for 80% of patients; 52% were 65 years or older. At 1
year, patients starting HD with AVF had improved survival
compared to patients who initiated HD through TDC (88%
vs 76%; P < .001) or through AVG (88% vs 83%; P < .001).
In patients over 65 who initiate HD with TDC, creation of
AVF and AVG are associated with identical survival (P ¼
NS), with both signiﬁcantly better than continued HD
through TDC (P < .001) (Fig).
Conclusions: Initiation of HD through AVF is associ-
ated with improved survival compared to AVG and TDC,
but is a small fraction of ESRD patients. In patients over
65 that initiate HD through TDC, creation of AVF is
not superior to AVG in terms of survival.
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T. H. Yuo: Nothing to disclose.Fig.A Comparison of Patency Between One and Two Stage
Arteriovenous Fistula Transpositions
Alexander Chang, Matthew T. Allemang, Schmotzer Brian,
Lakin O. Ryan, Woodside J. Kenneth, Wang John, Vikram
S. Kashyap, Wong L. Virginia. University Hospitals of Case
Western Reserve University, Cleveland, Ohio
Objectives: Renewed interest in arteriovenous ﬁstula
(AVF) transposition has arisen as emphasis is being placed on
autologous hemodialysis access construction. We report our
experience with one and two stage techniques for AVF
transposition.
Methods: A database of all patients who had AVF
placed between January 2008 and June 2011 was retro-
spectively reviewed. Patients were stratiﬁed into those
whose AVF was transposed using a one stage technique
(AVFT-1) and those done with a two stage technique
(AVFT-2). Outcomes measured were assisted primary
and secondary patency. Marginal survival models utilizing
Cox proportional hazards regression were used for statis-
tical comparison. Results are reported as hazard ratio
(HR) and 95% conﬁdence intervals (CI).
Results: A total of 125 AVF were created using a trans-
position technique. AVFT-1 (n¼ 38) and AVFT-2 (n¼ 87)
were analyzed. After accounting for multivariate association
with age, diabetes, PAD, tobacco use, previous number of
accesses, and presence of tunneled catheter at AVF creation,
AVFT-2 was associated with both better assisted primary
(HR, 0.47; CI, 0.25-0.90) and secondary patency (HR,
0.44; CI, 0.23-0.87) when compared to AVFT-1.
Conclusions: In our experience two stage operations
demonstrated improved assisted primary and secondary
patency and as a corollary could extend the duration of
autologous access in challenging hemodialysis patients.
Author Disclosures: M. T. Allemang: Nothing to
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Nothing to disclose; W. John: Nothing to disclose;Fig. Kaplan-Meier survival curves of secondary patency for one-
stage and two-stage AVF transposition.
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Stent Migration: A Risk in the Treatment of Renal
Access Patients
Andrew J. Olinde1, Devin Conway1, Jay Hollman1, John
Schellack2, Paul Perkowski2, Joseph Grifﬁn1. 1Vascular
Specialty Center, Baton Rouge, La; 2Vascular Clinic,
Baton Rouge, La
Objectives: Central venous strictures often lead to
signiﬁcant arm swelling and access malformation in patients
with chronic renal failure. The purpose of this study is to
acknowledge the risk of stent migration in this subset of
patients treated for failing access grafts.
Methods: A retrospective chart review of patients
undergoing diagnostic ﬁstulagrams and percutanous inter-
vention of malfunctioning accesses was done from June
2007 to November 2012 in two major hospitals in Baton
Rouge, Louisiana. A total of 5184 ﬁstulagrams were per-
formed. 1189 (22.9%) procedures involved percutaneous
thrombectomy of the accesses. 2882 (55.6%) procedures
included balloon dilatation of the access or venous outﬂow
strictures. 796 (15.3%) patients had stents placed either in
the access or proximal central veins.
Results: Of the 796 stents placed in this series, six
migrated after deployment over varied time periods. Five
stents migrated to the heart requiring open heart surgical
removal. One patient had a stent migrate from the right
subclavian vein to the innominate vein.
Conclusions: Migration of stents can occur in the treat-
ment of failing renal access grafts. This is the largest reported
series to date in the literature of such events in renal failure
patients. The majority of stents migrated to the heart. The
high ﬂow system generated by these renal access grafts and
eventual gradual central vein dilatation in this patient popula-
tion increase the risk of future migration. Interventionalists
must be cognizant of this potential complication with the
need for selective accurate placement of stents.Despite proper
placement, stent migration may be unavoidable.
Author Disclosures: D. Conway: Nothing to disclose;
J. Grifﬁn: Nothing to disclose; J. Hollman: Nothing to
disclose; A. J. Olinde: Nothing to disclose; P. Perkowski:
Nothing to disclose; J. Schellack: Nothing to disclose.Table.
Patients 1 2 3 4 5
BM-bare metal
CS-covered
10 mm  26 mm BM 7 mm  40 mm CS 9 mm  40 mm BM 10 mm  60 mm
BM 12 mm  60 mm BM
11 mm  100 mm
CS
Location placed Subclavian vein Proximal access graft Basilic vein Common and external
iliac veins
Subclavian vein
Migration
diagnosed
4 days Same day 3 years 6 weeks 8 months
Migration destiniation Tricuspid valve Pulmonary valve Tricuspid valve Right atrium and right ventricle Innominate vein
Treatment Open heart retrieval Open heart retrieval Postmortem retrieval Open heart retrieval Balloon dilatation
of stentPS82.
Race and Insurance Status Have Limited Effect on
Long-Term Vascular Access Outcomes in Patients at
an Inner City University Hospital
Jeffrey J. Siracuse, Adi Wollstein, Yuriy Kotsurovskyy,
Diana Catz, Irene Epelboym, In-Kyong Kim, Heather
L. Gill, Nicholas J. Morrissey. New York-Presbyterian
Hospital, Columbia University, College of Physicians
and Surgeons, New York, NY
Objectives: Insurance status and race are potential
barriers to health care maintenance. We assessed their
contribution to upper extremity vascular access outcomes
in our population.
Methods: We retrospectively reviewed outcomes of
601 vascular access patients from 2004-2012 at our institu-
tion. We recorded patient demographics, comorbidities,
and complications. Primary outcomes were reintervention,
long-term mortality, and kidney transplantation.
Results: Arteriovenous ﬁstulas (AVF) accounted for
majority (66%) of operations. Median age was 62, 58%
were male. Race, a self-reported variable, was 50%Hispanic,
22% white, and 19% black. Most had Medicare only (42%),
while 31% had private insurance and 27% had Medicaid.
Black patients were less likely to get an AVF compared to
whites and Hispanics (P < .05). White patients were signif-
icantly older than either Hispanics or blacks (68 vs 61 vs 58;
P< .05). Overall freedom from reintervention at 5 years was
55%, with infection (HR, 2.0; 95% CI, 1.3-3.0), stenosis
(HR, 3.2; 95% CI, 2.3-4.3), thrombosis (HR, 1.7; 95%
CI, 1.2-2.4), and nerve injury (HR, 4.1; 95% CI, 1.5-
11.5) being independent predictors of reintervention.
Mortality at 5 years was 35%, predicted by AV graft place-
ment (HR, 1.9; 95% CI, 1.4-2.7), low albumin (HR, 0.7;
95% CI, 0.6-0.9), white race (HR, 1.9; 95% CI, 1.3-2.8),
and not receiving a kidney transplant (HR, 0.3; 95% CI,
0.2-0.6). Transplantation rate was 31% at 5 years and pre-
dicted by high albumin (HR, 1.9; 95% CI, 1.4-2.6), AVF
(HR, 1.6; 95%, 1.1-2.6), and no CAD (HR, 0.6; 95% CI,
0.4-0.9). Race and insurance status did not affect reinterven-
tion or transplantation rate.
Conclusions: Controlling for patient and clinical
factors, insurance status did not have a signiﬁcant effect
on long term vascular access outcomes in our population.
Race was not signiﬁcantly associated with reintervention
or transplantation, however more black patients had less
suitable vasculature for AVF, and white patients had a lower
long term survival, possibly due to more advanced age.
